latanoprost liposomal (POLAT 001) / Avid Bioservices - LARVOL DELTA

Sustained intraocular pressure lowering from suprachoroidal injection of a latanoprost lipid nanoparticle delivery system in the rabbit. (PubMed, Front Med (Lausanne)) - "Safety assessment of the eyes showed no adverse events and good tolerability of the drug. A single dose of liposomal latanoprost into the suprachoroidal space can lower the IOP for up to 56 days making it a promising therapeutic agent for sustained delivery drugs to the suprachoroidal space."

Journal • Preclinical • Glaucoma • Ophthalmology

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: Peregrine Ophthalmic | Active, not recruiting ➔ Completed

Trial completion

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Peregrine Ophthalmic | Recruiting ➔ Active, not recruiting

Enrollment closed

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Peregrine Ophthalmic | Trial completion date: Feb 2024 ➔ Jun 2024 | Trial primary completion date: Jan 2024 ➔ May 2024

Trial completion date • Trial primary completion date

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Peregrine Ophthalmic | Trial completion date: Nov 2023 ➔ Feb 2024

Trial completion date

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Peregrine Ophthalmic

New P1 trial

Comparison of Soluble and Liposome Encapsulated, Sustained Release Latanoprost for Focal Adipose Reduction. (PubMed, Facial Plast Surg Aesthet Med) - "Objective: To evaluate the safety and efficacy of soluble and liposomal latanoprost for focal fat reduction. Hematoxylin and eosin demonstrated effective reduction in adipocyte volume without histologic evidence of cytolysis or inflammation whereas DOCA caused dermal ulcerations, adipocyte lysis, and increased tissue inflammation. Latanoprost reduced fat volume without inducing cell lysis or inflammation."

Journal • Glaucoma • Immunology • Inflammation • Obesity • Ophthalmology

POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma (clinicaltrials.gov) - P2; N=81; Completed; Sponsor: Peregrine Ophthalmic; Active, not recruiting ➔ Completed

Trial completion • Biosimilar • Cardiovascular • Glaucoma • Ophthalmology